<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ometendo</journal-id><journal-title-group><journal-title xml:lang="ru">Ожирение и метаболизм</journal-title><trans-title-group xml:lang="en"><trans-title>Obesity and metabolism</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2071-8713</issn><issn pub-type="epub">2306-5524</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/omet12850</article-id><article-id custom-type="elpub" pub-id-type="custom">ometendo-12850</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Клинико-фармакологические основы применения лекарственных препаратов тестостерона для заместительной гормональной терапии при гипогонадизме у мужчин</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and pharmacological basis of the use of testosterone drugs for hormonal replacement therapy for hypogonadism in men</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4874-7835</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Волкова Наталья Ивановна, д.м.н., профессор</p><p>eLibrary SPIN: 3146-8337</p><p>344022, Ростов-на-Дону, пер. Нахичеванский, 29</p></bio><bio xml:lang="en"><p>Natalya I. Volkova, MD, PhD, Professor</p><p>eLibrary SPIN: 3146-8337</p><p>Rostov-on-Don, Nachichevansky street, 29</p></bio><email xlink:type="simple">n_i_volkova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4625-6186</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сафроненко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Safronenko</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сафроненко Андрей Владимирович, д.м.н., доцент</p><p>eLibrary SPIN: 3448-9574</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Andrey V. Safronenko, MD, PhD, Associate</p><p>eLibrary SPIN: 3448-9574</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">andrejsaf@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0627-8372</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ганцгорн</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gantsgorn</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ганцгорн Елена Владимировна, к.м.н., доцент</p><p>eLibrary SPIN: 4797-6070</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Elena V. Gantsgorn, MD, PhD, Associate Professor</p><p>eLibrary SPIN: 4797-6070</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">gantsgorn@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5838-4383</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дегтярева</surname><given-names>Ю. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Degtyareva</surname><given-names>Yu. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дегтярева Юлия Сергеевна, аспирант</p><p>eLibrary SPIN: 8935-5325</p><p>Ростов-на-Дону</p></bio><bio xml:lang="en"><p>Yuliya S. Degtyareva, MD, postgraduate student</p><p>eLibrary SPIN: 8935-5325</p><p>Rostov-on-Don</p></bio><email xlink:type="simple">yu.s.degtyareva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov state medical university</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>03</day><month>08</month><year>2022</year></pub-date><volume>19</volume><issue>2</issue><fpage>233</fpage><lpage>241</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Волкова Н.И., Сафроненко А.В., Ганцгорн Е.В., Дегтярева Ю.С., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Волкова Н.И., Сафроненко А.В., Ганцгорн Е.В., Дегтярева Ю.С.</copyright-holder><copyright-holder xml:lang="en">Volkova N.I., Safronenko A.V., Gantsgorn E.V., Degtyareva Y.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.omet-endojournals.ru/jour/article/view/12850">https://www.omet-endojournals.ru/jour/article/view/12850</self-uri><abstract><p>Гипогонадизм — состояние, ассоциированное со снижением функциональной активности яичек, сопровождающееся снижением уровня андрогенов и (или) нарушением процесса сперматогенеза. Общеизвестно, что гормоны-андрогены и их главный представитель — тестостерон имеют основополагающее значение для развития и сохранения сексуальной и репродуктивной функций мужской половой системы. При этом сниженный показатель тестостерона связан с нарушениями не только репродуктивной функции, но и метаболизма, включая фосфорно-кальциевый, жировой, углеводный и белковый обмен. Кроме этого, к настоящему времени накоплены данные о корреляции гипогонадизма с сердечно-сосудистыми заболеваниями, что лишний раз подчеркивает проблему дефицита тестостерона, особенно для пациентов средней и старшей возрастных групп. Однако проведение тестостеронзаместительной терапии всегда требует от специалиста строгого и грамотного выбора «целевой аудитории» среди пациентов. На сегодняшний день на фармацевтическом рынке существует довольно широкий арсенал тестостеронсодержащих лекарственных средств в различных формах для применения, которые имеют неодинаковый профиль «эффективность-безопасность». В данном обзоре нами были проанализированы современные подходы к диагностике, лечению гипогонадизма, отбору целевой группы пациентов для получения максимально эффективного и безопасного результата терапии, а также описаны препараты тестостерона и их лекарственные формы с потенциальными достоинствами и недостатками. Таким образом, информация, представленная в статье, направлена на оптимизацию ведения мужчин с гипогонадизмом.</p></abstract><trans-abstract xml:lang="en"><p>Hypogonadism is a condition associated with a decrease in the functional activity of the testicles, accompanied by a decrease in the level of androgens and (or) a violation of the process of spermatogenesis. It is known that androgens and their main representative, testosterone, are of fundamental importance for the development and maintenance of the reproductive and sexual functions of the male reproductive system. At the same time, low testosterone levels are associated with both reproductive and metabolic disorders, including phosphorus-calcium, fat, carbohydrate, and protein metabolism. In addition, to date, data have been accumulated on the correlation of hypogonadism with cardiovascular diseases, which once again emphasizes the problem of testosterone deficiency, especially for patients of the middle and older age groups. However, carrying out testosterone replacement therapy always requires a strict and competent choice of a «target audience» among patients from a specialist. Today, on the pharmaceutical market, there is a wide arsenal of testosterone-containing drugs in various forms for use, which have an unequal «efficacy-safety» profile. In this review, we have analyzed modern approaches to the diagnosis and treatment of hypogonadism, the selection of a target group of patients to obtain the most effective and safe treatment outcome and described testosterone preparations and their dosage forms with potential advantages and disadvantages. Thus, the information presented in the article is aimed at optimizing the management of men with hypogonadism.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тестостерон</kwd><kwd>гипогонадизм</kwd><kwd>диагностика</kwd><kwd>заместительная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>testosterone</kwd><kwd>hypogonadism</kwd><kwd>diagnosis</kwd><kwd>replacement therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Роживанов Р.В., и др. Рекомендации по диагностике и лечению гипогонадизма (дефицита тестостерона) у мужчин. Проект // Проблемы эндокринологии. — 2015. — T. 61. — №5 — C. 60-71. doi: https://doi.org/10.14341/probl20156560-71</mixed-citation><mixed-citation xml:lang="en">Dedov II, Melnichenko GA, Rozhivanov RV, et al. Clinical guide diagnisis and treatment gipogonadism (geficit of testosteron). The project. Problems of Endocrinology. 2015;61(5):60-71. (In Russ). doi: https://doi.org/10.14341/probl20156560-71</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Демидова Т.Ю., Скуридина Д.В. Использование трансдермальных тестостеронсодержащих гелей для коррекции эндокринной патологии в свете доказательной медицины // Русский медицинский журнал. Медицинское обозрение. — 2019. — Т. 3. — №10-2. — С. 96-100.</mixed-citation><mixed-citation xml:lang="en">Demidova TYu, Skuridina DV. Testosterone transdermal gels for endocrine disorders from the viewpoint of evidence-based medicine. Russkij medicinskij zhurnal. Medicinskoe obozrenie. 2019;3(10-2);96-100. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Тишковский С.В., Никонова Л.В. Мужской гипогонадизм: особенности диагностики и лечения // Лечебное дело: научнопрактический терапевтический журнал. — 2021. — Т. 2. — № 77. — С. 41-48.</mixed-citation><mixed-citation xml:lang="en">Tischovskii SV, Nikonova LV. Male hypogonadism: features of diagnosis and treatment. Lechebnoe delo: nauchnopracticheskii gurnal. 2021;2(77):41-48. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dohle (Chair) GR, Arver S, Bettocchi C, Jones TH, et al. EAU Guidelines on Male Hypogonadism. European Association of Urology; 2016. 26 p.</mixed-citation><mixed-citation xml:lang="en">Dohle (Chair) GR, Arver S, Bettocchi C, Jones TH, et al. EAU Guidelines on Male Hypogonadism. European Association of Urology; 2016. 26 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Аметов А.С., Пашкова Е.Ю. Эволюция тестостеронозаместительной терапии. Новые формы — новые возможности // Эндокринология: Новости. Мнения. Обучение. — 2017. — Т. 2. — №19. — С. 55-65.</mixed-citation><mixed-citation xml:lang="en">Ametov AS, Pashova EYu. Testosterone therapy evolution. New preparations — new benefits. Endocrinologia: Novosti. Mneniya. Obuchenie. 2017;2(19):55-65. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Калинченко С.Ю., Тюзиков И. А., Ворслов Л.О., и др. Пролонгированная инъекционная форма тестостерона ундеканоата для лечения мужского гипогонадизма: опыт 10-летнего клинического применения — от истории создания до современной доказательной базы эффективности и безопасности // Эффективная фармакотерапия. — 2015. — №35. — С. 24-33.</mixed-citation><mixed-citation xml:lang="en">Kalinchenko SYu, Tyuzikov IA, Vorslov LO, et al. A Prolonged Release Injectable Testosterone Undecanoate for Treatment of Male Hypogonadism: a 10-Year Experience of Clinical Usage — from a Story of Development to the Modern Evidence-Based Efficacy and Safety. Effektivnaya farmakoterapiya. 2015;35:24-33. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Arver S, Stief C, de la Rosette J, et al. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology. 2018;6(3):396-407. doi: https://doi.org/10.1111/andr.12487</mixed-citation><mixed-citation xml:lang="en">Arver S, Stief C, de la Rosette J, et al. A new 2% testosterone gel formulation: a comparison with currently available topical preparations. Andrology. 2018;6(3):396-407. doi: https://doi.org/10.1111/andr.12487</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi: https://doi.org/10.1016/j.juro.2018.03.115</mixed-citation><mixed-citation xml:lang="en">Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi: https://doi.org/10.1016/j.juro.2018.03.115</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: https://doi.org/10.1210/jc.2018-00229</mixed-citation><mixed-citation xml:lang="en">Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: https://doi.org/10.1210/jc.2018-00229</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Snyder PJ. Clinical features and diagnosis of male hypogonadism. UpToDate [Internet]. 2022. [cited 2022 Jun 01] Available from: https://www.uptodate.com/contents/clinical-features-and-diagnosis-ofmale-hypogonadism#!</mixed-citation><mixed-citation xml:lang="en">Snyder PJ. Clinical features and diagnosis of male hypogonadism. UpToDate [Internet]. 2022. [cited 2022 Jun 01] Available from: https://www.uptodate.com/contents/clinical-features-and-diagnosis-ofmale-hypogonadism#!</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., и др. Проект клинических рекомендаций «Синдром гипогонадизма у мужчин» // Ожирение и метаболизм. — 2021. — Т. 18. — №4. — С. 496-507. doi: https://doi.org/10.14341/omet12817</mixed-citation><mixed-citation xml:lang="en">Dedov II, Mokrysheva NG, Melnichenko GA, et al. Draft of Russian Clinical Practice Guidelines «Male hypogonadism». Obesity and metabolism. 2021;18(4):496-507. (In Russ.). doi: https://doi.org/10.14341/omet12817</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yeap BB, Wu FCW. Clinical practice update on testosterone therapy for male hypogonadism: Contrasting perspectives to optimize care. Clin Endocrinol (Oxf ). 2019;90(1):56-65. doi: https://doi.org/10.1111/cen.13888</mixed-citation><mixed-citation xml:lang="en">Yeap BB, Wu FCW. Clinical practice update on testosterone therapy for male hypogonadism: Contrasting perspectives to optimize care. Clin Endocrinol (Oxf ). 2019;90(1):56-65. doi: https://doi.org/10.1111/cen.13888</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Моргенталер А., Цицман М., Трэйш А.М., и др. Фундаментальные концепции, относящиеся к вопросам дефицита тестостерона и его лечения: консенсусные рекомендации группы международных экспертов // Ожирение и метаболизм. — 2016. — Т.13. — №3. — С. 15-31. doi: https://doi.org/10.14341/omet2016315-31</mixed-citation><mixed-citation xml:lang="en">Morgentaler A, Zitzmann M, Traish AM, et al. The consensus recommendations of a group of international experts on the fundamental concepts related to the issues of testosterone deficiency and its treatment. Obesity and metabolism. 2016;13(3):15-31. (In Russ.). doi: https://doi.org/10.14341/omet2016315-31</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ефремов Е.А., Красняк С.С. Возможные риски при терапии тестостероном // Экспериментальная и клиническая урология. — 2017. — Т. 1. — №1. — С. 90-96.</mixed-citation><mixed-citation xml:lang="en">Efremov EA, Krasnyak SS. Vozmozhnye riski pri terapii testosteronom. Eksperimentalnaya i clinicheskaya urologia. 2017;1(1):90-96. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64-69. doi: https://doi.org/10.3109/13685538.2015.1126573</mixed-citation><mixed-citation xml:lang="en">Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64-69. doi: https://doi.org/10.3109/13685538.2015.1126573</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Favilla V, Cimino S, Castelli T, et al. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int. 2010;106(11):1700-1703. doi: https://doi.org/10.1111/j.1464-410X.2010.09459.x</mixed-citation><mixed-citation xml:lang="en">Favilla V, Cimino S, Castelli T, et al. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int. 2010;106(11):1700-1703. doi: https://doi.org/10.1111/j.1464-410X.2010.09459.x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Trifiro MD, Parsons JK, Palazzi-Churas K, et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554-1559. doi: https://doi.org/10.1111/j.1464-410X.2009.09090.x</mixed-citation><mixed-citation xml:lang="en">Trifiro MD, Parsons JK, Palazzi-Churas K, et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 2010;105(11):1554-1559. doi: https://doi.org/10.1111/j.1464-410X.2009.09090.x</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, et al. The Efficacy and Adverse Events of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2018;103(5):1745-1754. doi: https://doi.org/10.1210/jc.2018-00404</mixed-citation><mixed-citation xml:lang="en">Ponce OJ, Spencer-Bonilla G, Alvarez-Villalobos N, et al. The Efficacy and Adverse Events of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review and Meta-Analysis of Randomized, Placebo-Controlled Trials. J Clin Endocrinol Metab. 2018;103(5):1745-1754. doi: https://doi.org/10.1210/jc.2018-00404</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Fernández-Balsells MM, Murad MH, Lane M. et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: https://doi.org/10.1210/jc.2009-2575</mixed-citation><mixed-citation xml:lang="en">Fernández-Balsells MM, Murad MH, Lane M. et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560-2575. doi: https://doi.org/10.1210/jc.2009-2575</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. doi: https://doi.org/10.1056/NEJMoa1506119</mixed-citation><mixed-citation xml:lang="en">Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. doi: https://doi.org/10.1056/NEJMoa1506119</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708-716. doi: https://doi.org/10.1001/jama.2016.21043</mixed-citation><mixed-citation xml:lang="en">Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708-716. doi: https://doi.org/10.1001/jama.2016.21043</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Diem SJ, Greer NL, MacDonald R, et al. Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2020;172(2):105-118. doi: https://doi.org/10.7326/M19-0830</mixed-citation><mixed-citation xml:lang="en">Diem SJ, Greer NL, MacDonald R, et al. Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Ann Intern Med. 2020;172(2):105-118. doi: https://doi.org/10.7326/M19-0830</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab (Seoul). 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760</mixed-citation><mixed-citation xml:lang="en">Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab (Seoul). 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Layton JB, Meier CR, Sharpless JL, et al. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med. 2015;175(7):1187. doi: https://doi.org/10.1001/jamainternmed.2015.1573</mixed-citation><mixed-citation xml:lang="en">Layton JB, Meier CR, Sharpless JL, et al. Comparative Safety of Testosterone Dosage Forms. JAMA Intern Med. 2015;175(7):1187. doi: https://doi.org/10.1001/jamainternmed.2015.1573</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Petering RC, Brooks NA. Testosterone Therapy: Review of Clinical Applications. Am Fam Physician. 2017;96(7):441-449.</mixed-citation><mixed-citation xml:lang="en">Petering RC, Brooks NA. Testosterone Therapy: Review of Clinical Applications. Am Fam Physician. 2017;96(7):441-449.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-R116. doi: https://doi.org/10.1530/EJE-15-0262</mixed-citation><mixed-citation xml:lang="en">Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-R116. doi: https://doi.org/10.1530/EJE-15-0262</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med. 2020;180(2):190-197. doi: https://doi.org/10.1001/jamainternmed.2019.5135</mixed-citation><mixed-citation xml:lang="en">Walker RF, Zakai NA, MacLehose RF, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA Intern Med. 2020;180(2):190-197. doi: https://doi.org/10.1001/jamainternmed.2019.5135</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247-1264. doi: https://doi.org/10.1517/14656566.2014.913022</mixed-citation><mixed-citation xml:lang="en">Surampudi P, Swerdloff RS, Wang C. An update on male hypogonadism therapy. Expert Opin Pharmacother. 2014;15(9):1247-1264. doi: https://doi.org/10.1517/14656566.2014.913022</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kang D-Y, Li H-J. The Effect of Testosterone Replacement Therapy on Prostate-Specific Antigen (PSA) Levels in Men Being Treated for Hypogonadism. Medicine (Baltimore). 2015;94(3):e410. doi: https://doi.org/10.1097/MD.0000000000000410</mixed-citation><mixed-citation xml:lang="en">Kang D-Y, Li H-J. The Effect of Testosterone Replacement Therapy on Prostate-Specific Antigen (PSA) Levels in Men Being Treated for Hypogonadism. Medicine (Baltimore). 2015;94(3):e410. doi: https://doi.org/10.1097/MD.0000000000000410</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Szeinbach SL, Enrique Seoane-Vazquez, Summers KH. Development of a men’s Preference for Testosterone Replacement Therapy (P-TRT) instrument. Patient Prefer Adherence. 2012;94(3):631. doi: https://doi.org/10.2147/PPA.S35840</mixed-citation><mixed-citation xml:lang="en">Szeinbach SL, Enrique Seoane-Vazquez, Summers KH. Development of a men’s Preference for Testosterone Replacement Therapy (P-TRT) instrument. Patient Prefer Adherence. 2012;94(3):631. doi: https://doi.org/10.2147/PPA.S35840</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Qaseem A, Horwitch CA, Vijan S, et al. Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2020;172(2):126. doi: https://doi.org/10.7326/M19-0882</mixed-citation><mixed-citation xml:lang="en">Qaseem A, Horwitch CA, Vijan S, et al. Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2020;172(2):126. doi: https://doi.org/10.7326/M19-0882</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J-D, Wu Y-Q. Anabolic-androgenic steroids and cardiovascular risk. Chinese Medical Journal. 2019;132(18):2229-2236. doi: https://doi.org/10.1097/cm9.0000000000000407</mixed-citation><mixed-citation xml:lang="en">Liu J-D, Wu Y-Q. Anabolic-androgenic steroids and cardiovascular risk. Chinese Medical Journal. 2019;132(18):2229-2236. doi: https://doi.org/10.1097/cm9.0000000000000407</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Yeo S, Holl K, Peñaherrera N, et al. Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review. Clin Outcomes Res. 2021;13(2):31-38. doi: https://doi.org/10.2147/CEOR.S285434</mixed-citation><mixed-citation xml:lang="en">Yeo S, Holl K, Peñaherrera N, et al. Burden of Male Hypogonadism and Major Comorbidities, and the Clinical, Economic, and Humanistic Benefits of Testosterone Therapy: A Narrative Review. Clin Outcomes Res. 2021;13(2):31-38. doi: https://doi.org/10.2147/CEOR.S285434</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Фадеева Е.А. Эффективность заместительной гормональной терапии у мальчиков с гипогонадизмом // Бюллютень медицинских интернет-конференций. — 2016. — №5. — С. 814.</mixed-citation><mixed-citation xml:lang="en">Fadeeva EA. Efficiency of hormonal replacement therapy in boys with hypogonadism. Bulletin of Medical Internet Conferences. 2016;5:814 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Swerdloff RS, Wang C, White WB, et al. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab. 2020;105(8):2515-2531. doi: https://doi.org/10.1210/clinem/dgaa238</mixed-citation><mixed-citation xml:lang="en">Swerdloff RS, Wang C, White WB, et al. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men. J Clin Endocrinol Metab. 2020;105(8):2515-2531. doi: https://doi.org/10.1210/clinem/dgaa238</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Patel M, Muthigi A, Ramasamy R. JATENZO®: Challenges in the development of oral testosterone. Int J Impot Res. 2021;105(8):2515-2531. doi: https://doi.org/10.1038/s41443-021-00461-4</mixed-citation><mixed-citation xml:lang="en">Patel M, Muthigi A, Ramasamy R. JATENZO®: Challenges in the development of oral testosterone. Int J Impot Res. 2021;105(8):2515-2531. doi: https://doi.org/10.1038/s41443-021-00461-4</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Newell-Price J, Huatan H, Quirke J, et al. An oral lipidic native testosterone formulation that is absorbed independent of food. Eur J Endocrinol. 2021;185(5):607-615. doi: https://doi.org/10.1530/EJE-21-0606</mixed-citation><mixed-citation xml:lang="en">Newell-Price J, Huatan H, Quirke J, et al. An oral lipidic native testosterone formulation that is absorbed independent of food. Eur J Endocrinol. 2021;185(5):607-615. doi: https://doi.org/10.1530/EJE-21-0606</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">DelConte A, Papangkorn K, Kim K, et al. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022;10(4):669-676. doi: https://doi.org/10.1111/andr.13153</mixed-citation><mixed-citation xml:lang="en">DelConte A, Papangkorn K, Kim K, et al. A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism. Andrology. 2022;10(4):669-676. doi: https://doi.org/10.1111/andr.13153</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Bruno BJ, Vangara K, Kim K, et al. TLANDO, a Novel Oral TRT, Improves Sexual and Mental Domain Outcomes in Hypogonadal Men. J Endocr Soc. 2021;5(S1):A495-A496. doi: https://doi.org/10.1210/jendso/bvab048.1012</mixed-citation><mixed-citation xml:lang="en">Bruno BJ, Vangara K, Kim K, et al. TLANDO, a Novel Oral TRT, Improves Sexual and Mental Domain Outcomes in Hypogonadal Men. J Endocr Soc. 2021;5(S1):A495-A496. doi: https://doi.org/10.1210/jendso/bvab048.1012</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Papangkorn K, Vangara K, Bruno BJ, et al. Efficacy and Safety of TLANDO, A Novel Oral Easy to Prescribe and Use TRT Option. J Endocr Soc. 2021;5(S1):A486-A486. doi: https://doi.org/10.1210/jendso/bvab048.994</mixed-citation><mixed-citation xml:lang="en">Papangkorn K, Vangara K, Bruno BJ, et al. Efficacy and Safety of TLANDO, A Novel Oral Easy to Prescribe and Use TRT Option. J Endocr Soc. 2021;5(S1):A486-A486. doi: https://doi.org/10.1210/jendso/bvab048.994</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">White WB, Bernstein JS, Rittmaster R, et al. Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men. J Clin Hypertens (Greenwich). 2021;23(7):1420-1430. doi: https://doi.org/10.1111/jch.14297</mixed-citation><mixed-citation xml:lang="en">White WB, Bernstein JS, Rittmaster R, et al. Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men. J Clin Hypertens (Greenwich). 2021;23(7):1420-1430. doi: https://doi.org/10.1111/jch.14297</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Saenger P, Steiner M. Oral testosterone undecanoate is an effective treatment for micropenis therapy. Pediatr Investig. 2021;5(4):323-324. doi: https://doi.org/10.1002/ped4.12304</mixed-citation><mixed-citation xml:lang="en">Saenger P, Steiner M. Oral testosterone undecanoate is an effective treatment for micropenis therapy. Pediatr Investig. 2021;5(4):323-324. doi: https://doi.org/10.1002/ped4.12304</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Manuel ML. Patient Satisfaction After Switching to Oral Testosterone Undecanoate. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT04983940?term=Oral+Testosterone+Undecanoate&amp;draw=3&amp;rank=12</mixed-citation><mixed-citation xml:lang="en">Manuel ML. Patient Satisfaction After Switching to Oral Testosterone Undecanoate. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT04983940?term=Oral+Testosterone+Undecanoate&amp;draw=3&amp;rank=12</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Denmeade S, Sullivan R. Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT05081193?term=Oral+Testosterone+Undecanoate&amp;draw=3&amp;rank=11</mixed-citation><mixed-citation xml:lang="en">Denmeade S, Sullivan R. Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT05081193?term=Oral+Testosterone+Undecanoate&amp;draw=3&amp;rank=11</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Dhindsa S, Newman J. Testosterone Treatment in Men With Chronic Kidney Disease. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT05249634?term=Oral+Testosterone+Undecanoate&amp;draw=4&amp;rank=28</mixed-citation><mixed-citation xml:lang="en">Dhindsa S, Newman J. Testosterone Treatment in Men With Chronic Kidney Disease. [Internet]. 2022. [cited 2022 Aug 01] Available from: https://clinicaltrials.gov/ct2/show/NCT05249634?term=Oral+Testosterone+Undecanoate&amp;draw=4&amp;rank=28</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
